Skip to main content
Shanghai ZJ Bio-Tech Co., Ltd logo

Shanghai ZJ Bio-Tech Co., Ltd — Investor Relations & Filings

Ticker · 688317 ISIN · CNE100005DB6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 547 across all filing types
Latest filing 2025-04-24 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688317

About Shanghai ZJ Bio-Tech Co., Ltd

https://m.liferiver.com.cn/

Shanghai ZJ Bio-Tech Co., Ltd., operating under the brand Liferiver, specializes in the development, manufacture, and distribution of molecular diagnostic reagents and equipment. The company’s core expertise lies in real-time PCR technology, providing a comprehensive portfolio of over 400 diagnostic kits. These solutions target a broad spectrum of infectious diseases, including viral hepatitis, respiratory infections, sexually transmitted diseases, and zoonotic pathogens. Beyond clinical diagnostics, the company offers specialized kits for food safety testing and veterinary health monitoring. Its products are utilized by clinical laboratories, hospitals, and public health institutions worldwide. Many diagnostic assays have achieved international recognition through CE marking and World Health Organization (WHO) listings. The company focuses on delivering high-sensitivity, high-specificity molecular tools to facilitate rapid pathogen detection and disease management.

Recent filings

Filing Released Lang Actions
独立董事提名人声明与承诺
Board/Management Information Classification · 95% confidence The document is a formal statement and commitment regarding the nomination of an independent director candidate for the company's board. It details the qualifications, independence criteria, and compliance with relevant laws and regulations for the nominee. There is no financial data, no report of financial performance, no voting results, no management changes announcement, and no mention of any report publication or regulatory filing. The content is focused on board/management information specifically about the nomination of a board member. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report but a substantive statement about board nomination.
2025-04-24 Chinese
之江生物：关于上海之江生物科技股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审计报告" (Special Audit Report) concerning non-operating fund occupation and other related party fund transactions for Shanghai Zhijiang Biotechnology Co., Ltd. It includes an audit opinion by a registered CPA, references to regulatory requirements from Chinese securities and banking regulators, and detailed financial tables summarizing related party transactions and fund usage for the year 2024. The document is about a specific audit engagement focusing on related party fund usage, not a full annual report or interim report. It is not a general audit report of financial statements but a specialized audit report on a particular issue, which fits the category of Audit Report / Information (AR). The document length is substantial (over 14,000 characters), indicating it is the report itself, not just an announcement. Therefore, the classification is AR with high confidence.
2025-04-24 Chinese
之江生物：2024年度独立董事述职报告（李学尧）
Board/Management Information Classification · 95% confidence The document is titled '2024年度独立董事述职报告(李学尧)' which translates to '2024 Annual Independent Director's Work Report'. It details the independent director's background, attendance at board and committee meetings, communication with auditors, oversight of company governance, and evaluation of company practices during the year 2024. It includes no financial statements or detailed financial data but focuses on the director's duties, observations, and opinions regarding governance and compliance. This type of document is a report by a board member on their management and oversight activities, fitting the category of Board/Management Information (MANG). The document length is 4087 characters, which is relatively short and focused on management reporting rather than a full annual report or audit report. Therefore, the appropriate classification is MANG with high confidence.
2025-04-24 Chinese
上海之江生物科技股份有限公司年度募集资金存放与使用情况鉴证报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "年度募集资金存放与使用情况鉴证报告" which translates to "Annual Verification Report on the Storage and Use of Raised Funds." It includes detailed information about the company's fundraising amounts, usage, balances, and management of raised funds for the year 2024. The document also contains an auditor's verification opinion and references to regulatory guidelines from the Shanghai Stock Exchange. The content focuses on the use and management of capital raised by the company, including cash management and investment of idle funds, which aligns with a capital/financing update rather than a full annual report or audit report. The document is substantive and detailed, not merely an announcement or certification letter, and it is not a general regulatory filing or a report publication announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-04-24 Chinese
国泰海通证券股份有限公司关于上海之江生物科技股份有限公司2024年度募集资金存放与使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from Guotai Huatong Securities Co., Ltd., acting as the sponsor institution, on the special inspection opinion regarding the deposit and use of raised funds by Shanghai Zhijiang Biotechnology Co., Ltd. for the year 2024. It includes comprehensive data on the amount of funds raised, their usage, management, storage, investment projects, and compliance with regulatory requirements. The document references specific regulatory guidelines related to the management and use of raised funds and provides detailed tables of fund usage and balances. The length of the document (15,000 characters) and the depth of financial and operational details indicate it is a substantive report rather than a brief announcement or certification. This aligns with the category of Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles related to regulatory inspections and fund usage verification, distinct from full annual reports or interim financial statements. Therefore, the document is best classified as an Audit Report / Information (AR).
2025-04-24 Chinese
之江生物：关于独立董事辞职及选举独立董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of an independent director and the election of a new independent director, including adjustments to the board committees. It discusses changes in the company's board of directors and committee memberships, referencing relevant laws and company bylaws. There is no financial data, earnings information, or report publication mentioned. The content fits the category of announcements about changes in the company's board or senior management.
2025-04-24 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.